Argenx to acquire peptide biotech for up to $1.15B
Amsterdam-based immunology innovation company Argenx will acquire Santa Cruz, Calif.-based biotech company Unnatural Products in a deal valued at up to about $1.15 billion. Under the agreement, Argenx will pay $550 million in cash upfront and up to $595 million more tied to development and regulatory milestones. It already holds a minority stake in Unnatural […] The post Argenx to acquire peptide biotech for up to $1.15B appeared first on Becker's Hospital Review | Healthcare News &a...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.